1043-3155 Pediatr Neurol Briefs pedneurbriefs Pediatr Neurol Briefs Pediatric Neurology Briefs Pediatr Neurol Briefs 2166-6482 1043-3155 2166-3155 Pediatric Neurology Briefs Publishers Chicago, IL, USA PNB-12-32-a 10.15844/pedneurbriefs-12-4-12 Attention Deficit and Learning Disorders Neurology Pediatrics Nervous System Diseases Child Development Brain Diseases Neurosurgery Child Infant Buspirone in ADHD http://orcid.org/0000-0002-0173-7931 Millichap J. Gordon MD 1 2 * Division of Neurology, Children's Memorial Hospital, Chicago, IL Departments of Pediatrics and Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL Correspondence: Dr. J. Gordon Millichap, E-mail: jgmillichap@northwestern.edu 04 1998 01 05 2016 12 4 32 32 Copyright: © 1998 The Author(s) 1998 This work is licensed under the Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. An open clinical trial of buspirone in children with attention-deficit/hyperactivity disorder

Buspirone monotherapy (0.5 mg/kg daily for 6 weeks) was evaluated in 12 children (10 boys, 2 girls), aged 6 to 12 years, with ADHD at the Maudsley Hospital, London, UK.

 Buspirone Dopaminergic Output Cognitive Function

Buspirone monotherapy (0.5 mg/kg daily for 6 weeks) was evaluated in 12 children (10 boys, 2 girls), aged 6 to 12 years, with ADHD at the Maudsley Hospital, London, UK. Compared to baseline scores on Conners Parent and other rating scales, all 12 patients showed significant improvements in hyperactivity, impulsivity, inattention, and disruptive behavior. Behaviors resumed on discontinuing Buspirone after 6 weeks. Mild dizziness occurred in 2 in the first week. [1]

COMMENT. Controlled trials of buspirone in larger samples of ADHD children seem justified. Buspirone is reported to increase noradrenergic and dopaminergic output, while modulating the serotonergic system. Used previously in children with anxiety, buspirone was tried in ADHD because of low toxicity and twice-daily regimen, not interfering with school schedules. All four dimensions of attention, hyperactivity, impulsivity, and behavioral problems improved, without rebound worsening of symptoms or development of tolerance. Effects on cognitive function need to be addressed, using psychological testing and teacher rating scales.

Malhotra S Santosh PJ An open clinical trial of buspirone in children with attention-deficit/hyperactivity disorder J Am Acad Child Adolesc Psychiatry 1998 Apr 37 4 364 371 10.1097/00004583-199804000-00013 9549956